Coppell Advisory Solutions’s AstraZeneca AZN Stock Holding History

Coppell Advisory Solutions’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,183	Closed	-$4.11M	–	563
2026 Q1	$4.11M	Buy	21,183 +12,617	+147%	+$2.43M	2.42%	7
2025 Q4	$1.58M	Sell	8,566 -1,061	-11%	-$186K	0.16%	133
2025 Q3	$1.43M	Sell	9,627 -580	-6%	-$87.8K	0.15%	145
2025 Q2	$1.43M	Sell	10,207 -1,852	-15%	-$260K	0.17%	129
2025 Q1	$1.73M	Sell	12,059 -4,556	-27%	-$659K	0.24%	101
2024 Q4	$2.18M	Buy	16,615 +7,169	+76%	+$1M	0.3%	68
2024 Q3	$1.47M	Buy	9,446 +95	+1%	+$15.3K	0.22%	99
2024 Q2	$1.46M	Buy	+9,351	New	+$1.41M	0.24%	90
2023 Q4	$39.6K	Buy	294 +191	+185%	+$24.8K	0.01%	547
2023 Q3	$14K	Buy	103 +3	+3%	+$410	﹤0.01%	549
2023 Q2	$14.3K	Buy	+100	New	+$14.7K	﹤0.01%	620
2023 Q1	–	Sell	-103	Closed	-$14K	–	263
2022 Q4	$14K	Buy	+103	New	+$12.9K	﹤0.01%	556

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Coppell Advisory Solutions's AZN Position: Q2 2026 in Review

Coppell Advisory Solutions sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 21,183 shares — an estimated $4.11M sold.

Coppell Advisory Solutions first reported a position in AZN in Q4 2022 and held it in 12 quarters. The position peaked at $4.11M in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Coppell Advisory Solutions reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Coppell Advisory Solutions sold 21,183 AstraZeneca shares in Q2 2026, an estimated $4.11M.
Coppell Advisory Solutions first reported a position in AstraZeneca in Q4 2022 and held it in 12 quarters.
Coppell Advisory Solutions's AstraZeneca position peaked at $4.11M in Q1 2026.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.